📣 VC round data is live. Check it out!
- Public Comps
- Sera Prognostics
Sera Prognostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sera Prognostics and similar public comparables like Senzime, Outset Medical, Applied BioCode, FluoGuide and more.
Sera Prognostics Overview
About Sera Prognostics
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Founded
2008
HQ

Employees
64
Website
Financials (LTM)
EV
$33M
Valuation Multiples
Start free trialSera Prognostics Financials
Sera Prognostics reported last 12-month revenue of $215K and negative EBITDA of ($36M).
In the same LTM period, Sera Prognostics generated $1K in gross profit, ($36M) in EBITDA losses, and had net loss of ($32M).
Revenue (LTM)
Sera Prognostics P&L
In the most recent fiscal year, Sera Prognostics reported revenue of $81K and EBITDA of ($31M).
Sera Prognostics is unprofitable as of last fiscal year, with gross margin of (102%), EBITDA margin of (38246%), and net margin of (39417%).
Financial data powered by Morningstar, Inc.
Sera Prognostics Stock Performance
Sera Prognostics has current market cap of $78M, and enterprise value of $33M.
Market Cap Evolution
Sera Prognostics' stock price is $1.99.
Sera Prognostics share price increased by 2.6% in the last 30 days, and by 27.6% in the last year.
Sera Prognostics has an EPS (earnings per share) of $-0.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $33M | $78M | 0.0% | 2.6% | -13.1% | 27.6% | $-0.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSera Prognostics Valuation Multiples
Sera Prognostics trades at 153.8x EV/Revenue multiple, and (0.9x) EV/EBITDA.
EV / Revenue (LTM)
Sera Prognostics Financial Valuation Multiples
As of May 26, 2026, Sera Prognostics has market cap of $78M and EV of $33M.
Sera Prognostics has a P/E ratio of (2.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sera Prognostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sera Prognostics Margins & Growth Rates
Sera Prognostics grew revenue by 413% and EBITDA by 19% in the last fiscal year.
In the most recent fiscal year, Sera Prognostics reported gross margin of (102%), EBITDA margin of (38246%), and net margin of (39417%).
Sera Prognostics Margins
Sera Prognostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sera Prognostics Operational KPIs
Sera Prognostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.6M for the same period.
Sera Prognostics' Rule of 40 is (8472%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sera Prognostics' Rule of X is (7853%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Sera Prognostics Competitors
Sera Prognostics competitors include Senzime, Outset Medical, Applied BioCode, FluoGuide, Creo Medical Group, Medicalgorithmics, Meta Biomed, LENSAR, Optiscan Imaging and Susmed.
Most Sera Prognostics public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.1x | 5.2x | (6.4x) | (8.3x) | |||
| 0.2x | 0.2x | (0.5x) | (0.6x) | |||
| 4.2x | — | (14.0x) | — | |||
| — | — | (10.9x) | (9.8x) | |||
| 12.9x | 7.0x | (2.0x) | (4.1x) | |||
| 12.9x | 8.1x | (25.8x) | 326.5x | |||
| 1.1x | — | 5.6x | — | |||
| 1.1x | 1.2x | 314.0x | (87.2x) | |||
This data is available for Pro users. Sign up to see all Sera Prognostics competitors and their valuation data. Start Free Trial | ||||||
Sera Prognostics Funding History
Before going public, Sera Prognostics raised $215M in total equity funding, across 7 rounds.
Sera Prognostics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sera Prognostics
| When was Sera Prognostics founded? | Sera Prognostics was founded in 2008. |
| Where is Sera Prognostics headquartered? | Sera Prognostics is headquartered in United States. |
| How many employees does Sera Prognostics have? | As of today, Sera Prognostics has over 64 employees. |
| Who is the CEO of Sera Prognostics? | Sera Prognostics' CEO is Evguenia Lindgardt. |
| Is Sera Prognostics publicly listed? | Yes, Sera Prognostics is a public company listed on Nasdaq. |
| What is the stock symbol of Sera Prognostics? | Sera Prognostics trades under SERA ticker. |
| When did Sera Prognostics go public? | Sera Prognostics went public in 2021. |
| Who are competitors of Sera Prognostics? | Sera Prognostics main competitors include Senzime, Outset Medical, Applied BioCode, FluoGuide, Creo Medical Group, Medicalgorithmics, Meta Biomed, LENSAR, Optiscan Imaging, Susmed. |
| What is the current market cap of Sera Prognostics? | Sera Prognostics' current market cap is $78M. |
| What is the current revenue of Sera Prognostics? | Sera Prognostics' last 12 months revenue is $215K. |
| What is the current revenue growth of Sera Prognostics? | Sera Prognostics revenue growth (NTM/LTM) is 591%. |
| What is the current EV/Revenue multiple of Sera Prognostics? | Current revenue multiple of Sera Prognostics is 153.8x. |
| Is Sera Prognostics profitable? | No, Sera Prognostics is not profitable. |
| What is the current EBITDA of Sera Prognostics? | Sera Prognostics has negative EBITDA and is not profitable. |
| What is Sera Prognostics' EBITDA margin? | Sera Prognostics' last 12 months EBITDA margin is (16821%). |
| What is the current EV/EBITDA multiple of Sera Prognostics? | Current EBITDA multiple of Sera Prognostics is (0.9x). |
| How many companies Sera Prognostics has acquired to date? | Sera Prognostics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Sera Prognostics has invested to date? | Sera Prognostics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Sera Prognostics
Lists including Sera Prognostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.